Screening for Chronic Obstructive Pulmonary Disease
US Preventive Services Task Force, Carol M. Mangione, Michael J. Barry, Wanda K. Nicholson, Michael D. Cabana, Aaron B. Caughey, David Chelmow, Tumaini R. Coker, Esa M. Davis, Katrina E Donahue, Carlos Roberto Jaén, Martha Kubik, Li Li, Gbenga Ogedegbe, Lori Pbert, John Ruiz, James Stevermer, Chien‐Wen Tseng, John B. Wong
Abstract
Importance: Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US. Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults. Population: Asymptomatic adults who do not recognize or report respiratory symptoms. Evidence Assessment: Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit. Recommendation: The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation).